Peds is about a 1B opportunity annually and there is no competition. Pretty easy to get to a valuation IMO once you can assess probability of success when you see the phase 2 data. The adult market is the cherry on top. JNJ and PFE each felt the opportunity was large enough to step in at an earlier phase for half a billion or more in the recent past. It’s getting good data at this stage that has been elusive so if ENTA really hits (say .8 log or more and some clinical trend) the market and / or pharma should come around. JMO
Jinx? Not. ENTA went up the day after my post. ;) On another note, Jay Luly announced on the Baird Global call that Enanta will be announcing another immunology candidate before year end.
Market Data 
Markets 
AI
